Polycystic liver disease or Autosomal dominant polycystic kidney disease with liver cyst
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: -Patients who participated in [Multi institutional joint research of efficacy and safety of Transcatheter Arterial Embolization with Embosphere for Polycystic liver disease] or[A study of efficacy and safety of Transcatheter Arterial Embolization (TAE) with Embosphere for Polycystic liver disease] -Patients from whom written informed consent to participate in this trial has been obtained after sufficient explanation receiving and having understanding
Exclusion criteria
Exclusion criteria: -Not eligible for this study based on the decision 's of a physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| QOL evolution and Change in QOL evolution after TAE | — |
Secondary
| Measure | Time frame |
|---|---|
| -Liver volume and the volume reduction rate of the liver -Liver cyst volume and the volume reduction rate of the liver cyst -Treatment rerated Adverse events | — |
Countries
Japan
Contacts
Hokkaido University Hospital Clinical Research and Medical Innovation Center